<DOC>
	<DOCNO>NCT01360385</DOCNO>
	<brief_summary>Recent study show remarkably positive effect 6 monthly injection Ranibizumab eye CRVO . The disease may cause severe sight threaten complication , partly due restriction blood flow oxygenation . Although Ranibizumab show affective reduce oedema retina , know whether drug ameliorates aggravate restriction oxygenation . The Oxymap oximeter allow non-invasive measurement oxygen saturation retinal vessel thus state retinal oxygenation . The primary objective study evaluate effect injection Ranibizumab retinal oxygen saturation eye newly diagnose central retinal vein occlusion ( CRVO ) , The secondary objective evaluate effect injection Ranibizumab visual acuity retinal oedema eye different degree ischemia .</brief_summary>
	<brief_title>Retinal Ischemia Central Retinal Vein Occlusion , Effects Treatment With Intravitreal Ranibizumab</brief_title>
	<detailed_description>Background objectives The CRUISE study show remarkable positive effect 6 monthly injection intravitreal Ranibizumab visual function eye macular edema secondary CRVO . Eyes CRVO risk severe complication retinal ischemia , particularly proliferative retinopathy neovascular glaucoma . It know whether intravitreal anti-VEGF therapy ameliorate aggravate retinal ischemia thus risk ischemic complication unknown . Since complication retinal ischemia take time develop , relatively infrequent , CRUISE study design , power , investigate impact intravitreal anti-VEGF treatment complication . The Oxymap oximeter allow objective non-invasive measurement oxygen saturation retinal vessel thus degree retinal ischemia . The rationale behind present study use instrument order obtain preliminary information effect intravitreal anti-VEGF treatment retinal ischemia CRVO eye without wait ischemic complication arise large study population . The primary objective study evaluate effect treatment intravitreal Ranibizumab retinal oxygen saturation eye newly diagnose central retinal vein occlusion ( CRVO ) , The secondary objective evaluate effect intravitreal Ranibizumab visual acuity central retinal thickness eye different degree ischemia . Study design The research project case-series study CRVO-patients three monthly injection Ranibizumab 3 month follow-up period , Ranibizumab injection provide need .</detailed_description>
	<mesh_term>Ischemia</mesh_term>
	<mesh_term>Retinal Vein Occlusion</mesh_term>
	<mesh_term>Endothelial Growth Factors</mesh_term>
	<mesh_term>Ranibizumab</mesh_term>
	<criteria>1 . Central retinal vein occlusion one eye . 2 . Planned treatment intravitreal injection Lucentis ( ranibizumab ) 3 . Functional fellow eye . 1 . Current previous medical condition opinion investigator may confound assessment study result put study method may put patient risk . 2 . Patients unable receive treatment vascular endothelial growth factor inhibitor . 3 . Prior panretinal photocoagulation study eye . 4 . Prior intraocular surgery study eye , cataract operation . 5 . Any intravitreal injection 6 month prior study baseline 6 . Participation another clinical study , opinion investigator , may confound assessment study result .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2012</verification_date>
	<keyword>Central retinal rein occlusion</keyword>
	<keyword>Retinal oximetry</keyword>
	<keyword>Oxymap Retinal Oximeter</keyword>
	<keyword>Visual acuity</keyword>
	<keyword>Central retinal thickness</keyword>
</DOC>